object
examin
serum
level
interferongammainduc
protein
inflammationinduc
chemokin
acut
myocardi
infarct
ami
design
method
subject
ami
patient
stabl
angina
pectori
patient
ap
normal
subject
ami
patient
blood
sampl
collect
percutan
coronari
intervent
pci
day
result
patient
ami
show
significantli
higher
serum
level
pgml
control
subject
pgml
patient
ap
pgml
serum
level
pci
neg
correl
infarct
size
indic
cumul
releas
creatin
kinas
ck
peak
ck
isoenzym
ckmb
stepwis
multipl
regress
analysi
reveal
serum
level
pci
independ
predictor
cumul
ck
releas
conclus
serum
level
increas
ami
higher
level
serum
pci
may
inform
regard
infarct
size
prognosi
acut
myocardi
infarct
ami
determin
sever
paramet
infarct
size
one
import
factor
affect
prognosi
mi
inflammatori
respons
ami
known
correl
infarct
size
aspect
inflammatori
respons
subsequ
heal
process
occur
ami
evalu
inflammatori
marker
includ
cytokin
blood
sampl
ami
patient
thu
inform
chemokin
chemotact
cytokin
initi
character
capac
induc
chemotaxi
migrat
leucocyt
play
import
role
inflammatori
respons
respons
inflamm
injuri
higher
level
chemokin
permit
attract
retent
specif
popul
lymphocyt
thu
chemokin
may
addit
effect
heal
infarct
beyond
leukotact
properti
chemokin
regul
angiogenesi
collagen
turnov
apoptosi
report
dysregul
endstag
heart
failur
chemokin
also
play
import
role
pathophysiolog
acut
coronari
syndrom
postinfarct
left
ventricular
remodel
chronic
heart
failur
interferongammainduc
protein
kda
also
refer
highli
induc
antiangiogen
protein
belong
cxc
chemokin
superfamili
increas
serum
level
report
atherosclerot
patient
experiment
myocardi
infarct
model
protein
shown
transient
induc
reperfus
myocardium
howev
whether
serum
level
increas
ami
patient
whether
serum
level
correl
infarct
size
indic
cumul
creatin
kinas
ck
releas
peak
ck
ck
isoenzym
mb
ckmb
ami
patient
never
examin
accordingli
examin
chang
serum
level
ami
patient
compar
cumul
ck
peak
ck
ckmb
studi
protocol
conform
declar
helsinki
approv
hospit
ethic
committe
written
inform
consent
obtain
patient
studi
elig
patient
firstami
patient
receiv
success
primari
percutan
coronari
intervent
pci
infarctrel
coronari
arteri
within
h
onset
total
consecut
patient
men
women
mean
age
year
ami
admit
cardiovascular
center
sakakibara
hospit
tsuyama
central
hospit
okayama
japan
januari
decemb
patient
stsegment
elev
mv
mi
two
lead
chest
pain
sustain
longer
min
patient
sever
respiratori
diseas
liver
diseas
kidney
diseas
concomit
inflammatori
diseas
infect
autoimmun
disord
malign
preexclud
studi
extent
atherosclerot
region
vessel
diagnos
xray
coronari
angiographi
stenosi
serum
ck
level
ckmb
level
determin
everi
h
first
second
day
admiss
day
valu
return
normal
rang
subject
stabl
angina
pectori
ap
n
men
women
mean
age
year
stabl
effort
angina
last
longer
month
diagnosi
confirm
coronari
angiographi
defin
n
narrow
lumin
diamet
least
one
diseas
vessel
control
subject
fig
serum
level
ami
patient
pci
box
plot
illustr
serum
level
control
subject
patient
stabl
angina
pectori
ap
acut
myocardi
infarct
pci
ami
patient
ami
higher
serum
level
control
subject
patient
ap
box
repres
percentil
whisker
indic
percentil
p
b
admiss
day
day
day
close
circl
indic
highest
tertil
serum
level
pci
close
box
indic
middl
tertil
close
triangl
indic
lowest
tertil
respect
note
highest
tertil
serum
level
pci
show
decreas
serum
level
day
other
increas
day
p
b
vs
lowest
tertil
studi
genderand
agematch
healthi
blood
donor
inform
consent
particip
studi
obtain
individu
collect
serum
blood
drawn
pyrogenfre
tube
without
addit
tube
immedi
immers
ice
water
blood
allow
clot
h
centrifug
min
serum
store
analyz
ck
activ
measur
modifi
rosalski
method
control
rang
ck
obtain
ageand
gendermatch
volunt
upper
limit
rang
sd
mean
control
ck
activ
iul
activ
ckmb
measur
use
reagent
immuneinhibit
assay
kit
diatron
tokyo
japan
accord
establish
method
upper
limit
rang
control
ckmb
activ
iu
l
cumul
ck
releas
calcul
accord
modifi
method
report
norri
et
al
shell
et
al
blood
sampl
drawn
immedi
day
admiss
pci
day
ami
patient
enzym
link
immunoassay
elisa
perform
previous
report
serum
level
measur
use
onestep
sandwich
elisa
kit
human
r
system
minneapoli
mn
usa
elisa
kit
wide
use
detect
serum
level
varieti
diseas
measur
method
well
establish
normal
subject
diseas
patient
elsewher
briefli
monoclon
antibodi
human
use
captur
biotinyl
polyclon
antibodi
use
detect
recombin
human
serv
standard
lower
limit
sensit
pgml
intraassay
interassay
coeffici
variat
b
respect
investig
blind
level
determin
cumul
ck
releas
peak
ck
ckmb
left
ventriculographi
perform
inform
consent
patient
approxim
week
onset
ami
left
ventriculogram
analyz
use
digit
comput
soni
graphtec
digit
tokyo
japan
previous
report
briefli
enddiastol
volum
lv
edv
determin
use
electrocardiogram
record
simultan
cine
film
frame
nearest
peak
r
wave
electrocardiogram
ecg
frame
smallest
left
ventricular
lv
volum
taken
show
endsystol
volum
lv
esv
lv
volum
calcul
use
modif
dodg
formula
lv
volum
indic
avail
patient
compar
serum
level
index
bodi
surfac
area
data
express
mean
sd
differ
characterist
across
quartil
compar
anova
follow
bonferroni
post
hoc
test
continu
variabl
chisquar
test
dichotom
variabl
correl
stepwis
multipl
regress
analysi
use
assess
possibl
determin
cumul
ck
releas
analysi
adjust
perform
follow
variabl
age
gender
use
angiotensinconvert
enzym
inhibitorangiotensin
ii
receptor
blocker
calcium
blocker
aspirin
time
reperfus
culprit
lesion
thrombolysi
myocardi
infarct
timi
flow
grade
primari
pci
collater
flow
primari
pci
timi
flow
grade
pci
serum
level
pci
pgml
analys
perform
use
spss
window
spss
inc
chicago
il
statview
sa
institut
san
francisco
ca
p
valu
b
consid
signific
patient
ami
significantli
higher
level
pci
pgml
control
subject
patient
ap
pgml
p
respect
fig
time
cours
serum
level
patient
ami
satisfi
inclus
criteria
present
studi
investig
reveal
mean
level
serum
slightli
decreas
day
pgml
elev
day
pgml
continu
increas
day
pgml
shown
fig
serum
level
pci
significantli
higher
group
patient
multipl
vessel
diseas
fig
patient
classifi
tertil
accord
serum
level
pci
patient
classifi
highest
tertil
show
transient
decreas
serum
level
day
fig
accordingli
determin
differ
serum
level
admiss
day
day
calcul
delta
serum
ad
level
serum
level
delta
significantli
lower
patient
classifi
highest
tertil
data
shown
tabl
show
clinic
characterist
accord
tertil
serum
level
pci
differ
age
gender
incid
coronari
risk
factor
five
categori
medic
taken
time
reperfus
patient
classifi
highest
tertil
longer
patient
classifi
tertil
angiograph
find
compar
among
tertil
tabl
shown
fig
b
cumul
ck
releas
peak
ck
level
highest
tertil
serum
level
pci
significantli
lower
lowest
tertil
p
b
peak
ckmb
level
examin
patient
studi
also
show
trend
fig
signific
neg
correl
log
serum
level
pci
log
cumul
ck
releas
peak
ck
peak
ckmb
patient
enrol
present
studi
fig
fig
show
lv
ef
week
onset
ami
patient
classifi
lowest
tertil
wors
patient
classifi
middl
tertil
serum
level
pci
significantli
neg
correl
lv
esvi
lv
edvi
fig
c
stepwis
multipl
regress
analysi
serum
level
well
culprit
lesion
lad
left
anterior
descend
arteri
independ
predictor
fig
relationship
serum
level
pci
lv
function
ami
patient
relationship
tertil
serum
level
pci
lv
ef
week
ami
p
b
relationship
serum
level
pci
lv
esvi
b
edvi
c
correl
coeffici
p
valu
relationship
indic
stepwis
multipl
regress
analysi
perform
use
follow
variabl
age
gender
use
acearb
ca
blocker
aspirin
time
reperfus
culprit
lesion
thrombolysi
myocardi
infarct
timi
flow
grade
primari
pci
collater
flow
primari
pci
timi
flow
grade
pci
serum
level
admiss
pgml
cumul
ck
releas
tabl
time
reperfus
independ
predictor
cumul
ck
releas
studi
serum
level
found
increas
ami
patient
admiss
time
cours
releas
ami
determin
serum
level
admiss
shown
neg
correl
infarct
size
indic
cumul
ck
releas
peak
ck
ckmb
present
method
use
determin
serum
level
well
establish
intraand
interassay
coeffici
variat
suffici
small
accord
previou
report
serum
level
normal
subject
rang
pgml
pgml
studi
investig
serum
level
genderand
agematch
healthi
blood
donor
level
observ
studi
consist
level
report
previou
studi
use
elisa
assay
kit
indic
present
assay
method
appropri
result
valid
data
demonstr
serum
level
significantli
increas
ami
patient
prior
pci
compar
healthi
control
recent
accumul
evid
demonstr
elev
serum
level
variou
diseas
includ
inflammatori
diseas
shown
util
clinic
inform
marker
instanc
tang
et
al
report
earli
enhanc
induct
independ
predictor
outcom
sever
acut
respiratori
syndrom
sar
patient
myocardi
infarct
frangogianni
et
al
found
primarili
synthes
ischem
microvascular
endotheli
cell
enhanc
product
declin
within
h
reperfus
anim
ischemiareperfus
model
rothenbach
et
al
report
posit
correl
serum
level
sever
acutephas
protein
inflammationassoci
cytokin
coronari
heart
diseas
patient
aukrust
et
al
recent
review
use
serum
plasma
chemokin
level
predict
risk
cardiovascular
event
suggest
import
pathogen
role
chemokin
atherogenesi
plaqu
destabil
data
show
elev
serum
level
ami
line
report
addit
serum
level
rare
increas
stabl
angina
patient
studi
unstabl
angina
patient
enrol
serum
level
report
correl
inflammationassoci
cytokin
includ
therefor
postul
lack
increas
serum
level
ap
patient
studi
may
relat
plaqu
stabil
studi
demonstr
first
time
serum
level
chang
time
ami
mean
valu
serum
ami
patient
decreas
day
note
patient
classifi
highest
tertil
serum
level
pci
show
decreas
serum
level
day
indic
serum
level
increas
remark
pci
certain
condit
ami
patient
return
regular
infarct
heal
process
level
day
ami
increas
serum
level
prior
pci
may
relat
benefici
conditionssitu
ischem
heart
eg
ischem
precondit
transient
recan
arriv
hospit
could
identifi
studi
may
ami
patient
higher
serum
level
smaller
infarct
size
addit
serum
level
show
increas
mean
level
varianc
day
ami
littl
current
known
regul
ami
possibl
serum
level
increas
accord
develop
heart
failur
elev
chemokin
express
patient
heart
failur
report
may
least
part
explan
wide
variabl
serum
level
day
ami
studi
therefor
clinic
investig
patient
variou
cardiovascular
diseas
need
includ
monitor
serum
level
acut
chronic
heart
failur
studi
found
signific
neg
correl
serum
level
pci
infarct
size
indic
cumul
ck
releas
peak
ck
ckmb
mani
report
attempt
estim
myocardi
ischem
damag
measur
biomark
ami
patient
ahumada
et
al
review
studi
show
ckmb
highli
sensit
specif
biomark
myocardi
injuri
recent
novel
biomark
includ
troponin
tnt
troponin
tni
found
factor
evalu
estim
infarct
size
instanc
licka
et
al
report
serum
tnt
level
h
ami
peak
ck
significantli
correl
infarct
size
estim
uptak
score
myocardi
singl
photon
emiss
comput
tomographi
spect
younger
et
al
report
tni
level
h
ami
similarli
use
serial
ck
measur
estim
infarct
size
use
late
gadolinium
hyperenhanc
cardiac
magnet
reson
lgecmr
tanaka
et
al
report
peak
tnt
tni
level
correl
peak
ck
level
cumul
ck
releas
success
reperfus
ami
patient
di
chiara
et
al
report
peak
ck
best
predictor
infarct
size
firstami
patient
studi
indic
use
ck
releas
peak
ck
ckmb
estim
infarct
size
thu
cumul
ck
releas
peak
ck
ckmb
could
use
examin
relationship
serum
level
infarct
size
sever
limit
studi
first
present
studi
includ
small
number
patient
care
chose
patient
first
ami
follow
success
reperfus
primari
pci
without
diseas
complic
nevertheless
serum
level
significantli
correl
cumul
ck
releas
peak
ck
impli
find
shed
light
role
inform
biomark
ami
patient
studi
random
sampl
larger
popul
cours
requir
draw
definit
conclus
second
exclud
possibl
initi
high
serum
level
well
alter
serum
level
patient
present
studi
epiphenomenon
reflect
unknown
mechan
reduc
infarct
size
report
investig
serum
level
patient
sever
heart
diseas
acut
heart
failur
myocard
discuss
previou
section
clinic
investig
serum
level
alter
variou
cardiovascular
diseas
requir
conclus
detect
signific
increas
serum
level
ami
patient
measur
chemokin
may
provid
inform
regard
infarct
size
ami
patient
